The present invention relates to the genetic modification of bacteria of the genus Clostridium, typically solventogenic bacteria of the genus Clostridium, in particular bacteria possessing in the wild type a gene encoding an amphenicol-O-acetyltransferase. It thus relates to methods, tools and kits allowing such a genetic modification, in particular the removal or modification of a sequence encoding or controlling the transcription of an amphenicol-O-acetyltransferase, to the genetically modified bacteria obtained and to uses thereof, in particular for producing a solvent, preferably on an industrial scale.

A modified chloramphenicol acetyltransferase comprising a tyrosine residue 20 having a phenylalanine (Y20F) mutation, a microorganism harboring the modified chloramphenicol acetyltransferase, and a method of producing ester by feeding the microorganism are disclosed. The method includes providing the microorganism harboring a modified chloramphenicol acetyltransferase in an environment suitable for the microorganism to produce an ester and feeding the microorganism (i) a sugar or a cellulose, and (ii) an alcohol and/or a carboxylic acid.

A method for biologically producing acetin such as monoacetin, diacetin, or triacetin according to an embodiment of the present disclosure includes reacting acetyl-CoA with glycerol in the presence of a first O-acetyl transferase to obtain the acetin. With the method, acetin which is sustainable and safe, and has more excellent quality while not causing environmental pollution may be obtained.

The design, assembly, and use of novel sequences comprising targeting and insertion sites for site-specific bacterial transposons are disclosed. One aspect relates to a nucleotide sequence comprising an attachment site for a site-specific transposon operably-linked to a screenable or selectable marker sequence, wherein said marker sequence encodes one or more active or inactive polypeptides capable of conferring a screenable or selectable phenotype upon a cell comprising the marker sequence, wherein insertion of the site-specific transposon into the attachment site changes the phenotype of a cell comprising the screenable or selectable marker sequence. High and low copy number vectors comprising the sequences, designated synthemids, including plasmids capable of propagating in bacteria, and shuttle vectors, capable of propagating in bacteria and a eukaryotic host cell or two types of bacteria by means of distinct replicons, are also disclosed. Related aspects include the design and assembly of synthetic insect and mammalian virus shuttle vectors, including shuttle vectors comprising segments of a double-stranded DNA virus, such as a baculovirus, which propagates in insect cells, or a herpesvirus, an adenovirus, or a pox virus, which propagate in mammalian cells. Other aspects relate to use of modified vectors to express polypeptides for use as therapeutic drug products, as vaccines, or as components of cell or gene therapy vector systems, and in model and crop plant cells, tissues, and whole plants to facilitate the basic and applied studies leading to improved food products, and as tools advancing the interests of institutions involved in industrial and environmental biotechnology.

A system for expressing a chloramphenicol split protein is disclosed. Uses thereof are also disclosed.

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

A system for expressing a chloramphenicol split protein is disclosed. Uses thereof are also disclosed.

The present application provides a method of producing a liquid array of ligand (such as glycan) modified bacteriophage where the ligand modification is encoded genetically within the bacteriophage genome. This method will allow for the determination of the ligand binding profile of biomacromolecules and cells. Furthermore the method allows the elucidation of ligand-protein interactions where ligand binding is co-operative and synergistic.

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

A system for expressing a chloramphenicol split protein is disclosed. Uses thereof are also disclosed.